Colony Group’s Spero Therapeutics SPRO Stock Holding History

Colony Group’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$17K	–	857
2022 Q4	$17K	Buy	+10,000	New	+$18.7K	﹤0.01%	830

Other funds holding SPRO

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Colony Group's SPRO Position: Q1 2023 in Review

Colony Group sold out of Spero Therapeutics (SPRO) in Q1 2023, closing a stake of 10,000 shares — an estimated $17K sold.

Colony Group first reported a position in SPRO in Q4 2022 and held it in 1 quarter. The position peaked at $17K in Q4 2022. 48 funds tracked by Wall St. Rank hold SPRO as of Q1 2023.

Colony Group reported no remaining Spero Therapeutics position as of Q1 2023 after selling out during the quarter.
Colony Group sold 10,000 Spero Therapeutics shares in Q1 2023, an estimated $17K.
Colony Group first reported a position in Spero Therapeutics in Q4 2022 and held it in 1 quarter.
Colony Group's Spero Therapeutics position peaked at $17K in Q4 2022.
48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2023.

Based on Colony Group's 13F filing for Q1 2023, filed 16 May 2023.